Loading…

Adenosine [A.sub.3] agonists reverse neuropathic pain via T cell-mediated production of IL-10

The [A.sub.3] adenosine receptor ([A.sub.3]AR) has emerged as a therapeutic target with [A.sub.3]AR agonists to tackle the global challenge of neuropathic pain, and investigation into its mode of action is essential for ongoing clinical development. Immune cell [A.sub.3]ARs, and their activation dur...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of clinical investigation 2021-04, Vol.131 (7)
Main Authors: Durante, Mariaconcetta, Squillace, Silvia, Lauro, Filomena, Giancotti, Luigino Antonio, Coppi, Elisabetta, Cherchi, Federica, Mannelli, Lorenzo Di Cesare, Ghelardini, Carla, Kolar, Grant, Wahlman, Carrie, Opejin, Adeleye, Xiao, Cuiying, Reitman, Marc L, Tosh, Dilip K, Hawiger, Daniel, Jacobson, Kenneth A, Salvemini, Daniela
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue 7
container_start_page
container_title The Journal of clinical investigation
container_volume 131
creator Durante, Mariaconcetta
Squillace, Silvia
Lauro, Filomena
Giancotti, Luigino Antonio
Coppi, Elisabetta
Cherchi, Federica
Mannelli, Lorenzo Di Cesare
Ghelardini, Carla
Kolar, Grant
Wahlman, Carrie
Opejin, Adeleye
Xiao, Cuiying
Reitman, Marc L
Tosh, Dilip K
Hawiger, Daniel
Jacobson, Kenneth A
Salvemini, Daniela
description The [A.sub.3] adenosine receptor ([A.sub.3]AR) has emerged as a therapeutic target with [A.sub.3]AR agonists to tackle the global challenge of neuropathic pain, and investigation into its mode of action is essential for ongoing clinical development. Immune cell [A.sub.3]ARs, and their activation during pathology, modulate cytokine release. Thus, the use of immune cells as a cellular substrate for the pharmacological action of [A.sub.3]AR agonists is enticing, but unknown. The present study discovered that Rag- KO mice lacking T and B cells, as compared with WT mice, are insensitive to the anti-allodynic effects of [A.sub.3]AR agonists. Similar findings were observed in interleukin-10 and interleukin-10 receptor knockout mice. Adoptive transfer of [CD4.sup.+] T cells from WT mice infiltrated the dorsal root ganglion (DRG) and restored [A.sub.3]AR agonist-mediated anti-allodynia in Rag-KO mice. [CD4.sup.+] T cells from Adora3-KO or Il10-KO mice did not. Transfer of [CD4.sup.+] T cells from WT mice, but not Il10-KO mice, into Il10- KO mice or Adora3-KO mice fully reinstated the anti-allodynic effects of [A.sub.3]AR activation. Notably, [A.sub.3]AR agonism reduced DRG neuron excitability when cocultured with [CD4.sup.+] T cells in an IL-10-dependent manner. [A.sub.3]AR action on [CD4.sup.+] T cells infiltrated in the DRG decreased phosphorylation of GluN2B-containing N-methyl-D-aspartate receptors at Tyr1472, a modification associated with regulating neuronal hypersensitivity. Our findings establish that activation of [A.sub.3]AR on [CD4.sup.+] T cells to release IL-10 is required and sufficient evidence for the use of [A.sub.3]AR agonists as therapeutics.
doi_str_mv 10.1172/JCI139299
format article
fullrecord <record><control><sourceid>gale</sourceid><recordid>TN_cdi_gale_infotracmisc_A657723633</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A657723633</galeid><sourcerecordid>A657723633</sourcerecordid><originalsourceid>FETCH-LOGICAL-g289t-426c997f7f022cec05c72c0a0afe4be0d7a8b49c1905ebcae17fc26532b1ccfc3</originalsourceid><addsrcrecordid>eNqN0EtLAzEQB_AgCtbHwW8QEAQPW_PYbTbHUnxUCoKvi0jJzk62kW1SNtnix7eiBws9yBz-MPz-cxhCzjgbcq7E1f1kyqUWWu-RAS-KMiuFLPfJgDHBM61keUiOYvxgjOd5kQ_I-7hGH6LzSN_Gw9hXQ_lOTRO8iynSDtfYRaQe-y6sTFo4oCvjPF07Q58pYNtmS6ydSVjTVRfqHpILngZLp7OMsxNyYE0b8fQ3j8nLzfXz5C6bPdxOJ-NZ1ohSpywXI9BaWWWZEIDAClACmGHGYl4hq5Upq1wD16zACgxyZUGMCikqDmBBHpPzn7uNaXHuvA2pM7B0EebjUaGUkCMpNyrboRr02Jk2eLRus97ywx1-MzUuHewsXG4VNibhZ2pMH-N8-vT4f_vwum0v_tgFmjYtYmj771_Hv_ALy3Sbwg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Adenosine [A.sub.3] agonists reverse neuropathic pain via T cell-mediated production of IL-10</title><source>PubMed Central</source><source>EZB Electronic Journals Library</source><creator>Durante, Mariaconcetta ; Squillace, Silvia ; Lauro, Filomena ; Giancotti, Luigino Antonio ; Coppi, Elisabetta ; Cherchi, Federica ; Mannelli, Lorenzo Di Cesare ; Ghelardini, Carla ; Kolar, Grant ; Wahlman, Carrie ; Opejin, Adeleye ; Xiao, Cuiying ; Reitman, Marc L ; Tosh, Dilip K ; Hawiger, Daniel ; Jacobson, Kenneth A ; Salvemini, Daniela</creator><creatorcontrib>Durante, Mariaconcetta ; Squillace, Silvia ; Lauro, Filomena ; Giancotti, Luigino Antonio ; Coppi, Elisabetta ; Cherchi, Federica ; Mannelli, Lorenzo Di Cesare ; Ghelardini, Carla ; Kolar, Grant ; Wahlman, Carrie ; Opejin, Adeleye ; Xiao, Cuiying ; Reitman, Marc L ; Tosh, Dilip K ; Hawiger, Daniel ; Jacobson, Kenneth A ; Salvemini, Daniela</creatorcontrib><description>The [A.sub.3] adenosine receptor ([A.sub.3]AR) has emerged as a therapeutic target with [A.sub.3]AR agonists to tackle the global challenge of neuropathic pain, and investigation into its mode of action is essential for ongoing clinical development. Immune cell [A.sub.3]ARs, and their activation during pathology, modulate cytokine release. Thus, the use of immune cells as a cellular substrate for the pharmacological action of [A.sub.3]AR agonists is enticing, but unknown. The present study discovered that Rag- KO mice lacking T and B cells, as compared with WT mice, are insensitive to the anti-allodynic effects of [A.sub.3]AR agonists. Similar findings were observed in interleukin-10 and interleukin-10 receptor knockout mice. Adoptive transfer of [CD4.sup.+] T cells from WT mice infiltrated the dorsal root ganglion (DRG) and restored [A.sub.3]AR agonist-mediated anti-allodynia in Rag-KO mice. [CD4.sup.+] T cells from Adora3-KO or Il10-KO mice did not. Transfer of [CD4.sup.+] T cells from WT mice, but not Il10-KO mice, into Il10- KO mice or Adora3-KO mice fully reinstated the anti-allodynic effects of [A.sub.3]AR activation. Notably, [A.sub.3]AR agonism reduced DRG neuron excitability when cocultured with [CD4.sup.+] T cells in an IL-10-dependent manner. [A.sub.3]AR action on [CD4.sup.+] T cells infiltrated in the DRG decreased phosphorylation of GluN2B-containing N-methyl-D-aspartate receptors at Tyr1472, a modification associated with regulating neuronal hypersensitivity. Our findings establish that activation of [A.sub.3]AR on [CD4.sup.+] T cells to release IL-10 is required and sufficient evidence for the use of [A.sub.3]AR agonists as therapeutics.</description><identifier>ISSN: 0021-9738</identifier><identifier>EISSN: 1558-8238</identifier><identifier>DOI: 10.1172/JCI139299</identifier><language>eng</language><publisher>American Society for Clinical Investigation</publisher><subject>Care and treatment ; Cell receptors ; Development and progression ; Genetic aspects ; Health aspects ; Immune response ; Interleukins ; Peripheral nerve diseases</subject><ispartof>The Journal of clinical investigation, 2021-04, Vol.131 (7)</ispartof><rights>COPYRIGHT 2021 American Society for Clinical Investigation</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Durante, Mariaconcetta</creatorcontrib><creatorcontrib>Squillace, Silvia</creatorcontrib><creatorcontrib>Lauro, Filomena</creatorcontrib><creatorcontrib>Giancotti, Luigino Antonio</creatorcontrib><creatorcontrib>Coppi, Elisabetta</creatorcontrib><creatorcontrib>Cherchi, Federica</creatorcontrib><creatorcontrib>Mannelli, Lorenzo Di Cesare</creatorcontrib><creatorcontrib>Ghelardini, Carla</creatorcontrib><creatorcontrib>Kolar, Grant</creatorcontrib><creatorcontrib>Wahlman, Carrie</creatorcontrib><creatorcontrib>Opejin, Adeleye</creatorcontrib><creatorcontrib>Xiao, Cuiying</creatorcontrib><creatorcontrib>Reitman, Marc L</creatorcontrib><creatorcontrib>Tosh, Dilip K</creatorcontrib><creatorcontrib>Hawiger, Daniel</creatorcontrib><creatorcontrib>Jacobson, Kenneth A</creatorcontrib><creatorcontrib>Salvemini, Daniela</creatorcontrib><title>Adenosine [A.sub.3] agonists reverse neuropathic pain via T cell-mediated production of IL-10</title><title>The Journal of clinical investigation</title><description>The [A.sub.3] adenosine receptor ([A.sub.3]AR) has emerged as a therapeutic target with [A.sub.3]AR agonists to tackle the global challenge of neuropathic pain, and investigation into its mode of action is essential for ongoing clinical development. Immune cell [A.sub.3]ARs, and their activation during pathology, modulate cytokine release. Thus, the use of immune cells as a cellular substrate for the pharmacological action of [A.sub.3]AR agonists is enticing, but unknown. The present study discovered that Rag- KO mice lacking T and B cells, as compared with WT mice, are insensitive to the anti-allodynic effects of [A.sub.3]AR agonists. Similar findings were observed in interleukin-10 and interleukin-10 receptor knockout mice. Adoptive transfer of [CD4.sup.+] T cells from WT mice infiltrated the dorsal root ganglion (DRG) and restored [A.sub.3]AR agonist-mediated anti-allodynia in Rag-KO mice. [CD4.sup.+] T cells from Adora3-KO or Il10-KO mice did not. Transfer of [CD4.sup.+] T cells from WT mice, but not Il10-KO mice, into Il10- KO mice or Adora3-KO mice fully reinstated the anti-allodynic effects of [A.sub.3]AR activation. Notably, [A.sub.3]AR agonism reduced DRG neuron excitability when cocultured with [CD4.sup.+] T cells in an IL-10-dependent manner. [A.sub.3]AR action on [CD4.sup.+] T cells infiltrated in the DRG decreased phosphorylation of GluN2B-containing N-methyl-D-aspartate receptors at Tyr1472, a modification associated with regulating neuronal hypersensitivity. Our findings establish that activation of [A.sub.3]AR on [CD4.sup.+] T cells to release IL-10 is required and sufficient evidence for the use of [A.sub.3]AR agonists as therapeutics.</description><subject>Care and treatment</subject><subject>Cell receptors</subject><subject>Development and progression</subject><subject>Genetic aspects</subject><subject>Health aspects</subject><subject>Immune response</subject><subject>Interleukins</subject><subject>Peripheral nerve diseases</subject><issn>0021-9738</issn><issn>1558-8238</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNqN0EtLAzEQB_AgCtbHwW8QEAQPW_PYbTbHUnxUCoKvi0jJzk62kW1SNtnix7eiBws9yBz-MPz-cxhCzjgbcq7E1f1kyqUWWu-RAS-KMiuFLPfJgDHBM61keUiOYvxgjOd5kQ_I-7hGH6LzSN_Gw9hXQ_lOTRO8iynSDtfYRaQe-y6sTFo4oCvjPF07Q58pYNtmS6ydSVjTVRfqHpILngZLp7OMsxNyYE0b8fQ3j8nLzfXz5C6bPdxOJ-NZ1ohSpywXI9BaWWWZEIDAClACmGHGYl4hq5Upq1wD16zACgxyZUGMCikqDmBBHpPzn7uNaXHuvA2pM7B0EebjUaGUkCMpNyrboRr02Jk2eLRus97ywx1-MzUuHewsXG4VNibhZ2pMH-N8-vT4f_vwum0v_tgFmjYtYmj771_Hv_ALy3Sbwg</recordid><startdate>20210401</startdate><enddate>20210401</enddate><creator>Durante, Mariaconcetta</creator><creator>Squillace, Silvia</creator><creator>Lauro, Filomena</creator><creator>Giancotti, Luigino Antonio</creator><creator>Coppi, Elisabetta</creator><creator>Cherchi, Federica</creator><creator>Mannelli, Lorenzo Di Cesare</creator><creator>Ghelardini, Carla</creator><creator>Kolar, Grant</creator><creator>Wahlman, Carrie</creator><creator>Opejin, Adeleye</creator><creator>Xiao, Cuiying</creator><creator>Reitman, Marc L</creator><creator>Tosh, Dilip K</creator><creator>Hawiger, Daniel</creator><creator>Jacobson, Kenneth A</creator><creator>Salvemini, Daniela</creator><general>American Society for Clinical Investigation</general><scope>IOV</scope><scope>ISR</scope></search><sort><creationdate>20210401</creationdate><title>Adenosine [A.sub.3] agonists reverse neuropathic pain via T cell-mediated production of IL-10</title><author>Durante, Mariaconcetta ; Squillace, Silvia ; Lauro, Filomena ; Giancotti, Luigino Antonio ; Coppi, Elisabetta ; Cherchi, Federica ; Mannelli, Lorenzo Di Cesare ; Ghelardini, Carla ; Kolar, Grant ; Wahlman, Carrie ; Opejin, Adeleye ; Xiao, Cuiying ; Reitman, Marc L ; Tosh, Dilip K ; Hawiger, Daniel ; Jacobson, Kenneth A ; Salvemini, Daniela</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g289t-426c997f7f022cec05c72c0a0afe4be0d7a8b49c1905ebcae17fc26532b1ccfc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Care and treatment</topic><topic>Cell receptors</topic><topic>Development and progression</topic><topic>Genetic aspects</topic><topic>Health aspects</topic><topic>Immune response</topic><topic>Interleukins</topic><topic>Peripheral nerve diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Durante, Mariaconcetta</creatorcontrib><creatorcontrib>Squillace, Silvia</creatorcontrib><creatorcontrib>Lauro, Filomena</creatorcontrib><creatorcontrib>Giancotti, Luigino Antonio</creatorcontrib><creatorcontrib>Coppi, Elisabetta</creatorcontrib><creatorcontrib>Cherchi, Federica</creatorcontrib><creatorcontrib>Mannelli, Lorenzo Di Cesare</creatorcontrib><creatorcontrib>Ghelardini, Carla</creatorcontrib><creatorcontrib>Kolar, Grant</creatorcontrib><creatorcontrib>Wahlman, Carrie</creatorcontrib><creatorcontrib>Opejin, Adeleye</creatorcontrib><creatorcontrib>Xiao, Cuiying</creatorcontrib><creatorcontrib>Reitman, Marc L</creatorcontrib><creatorcontrib>Tosh, Dilip K</creatorcontrib><creatorcontrib>Hawiger, Daniel</creatorcontrib><creatorcontrib>Jacobson, Kenneth A</creatorcontrib><creatorcontrib>Salvemini, Daniela</creatorcontrib><collection>Opposing Viewpoints Resource Center</collection><collection>Gale In Context: Science</collection><jtitle>The Journal of clinical investigation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Durante, Mariaconcetta</au><au>Squillace, Silvia</au><au>Lauro, Filomena</au><au>Giancotti, Luigino Antonio</au><au>Coppi, Elisabetta</au><au>Cherchi, Federica</au><au>Mannelli, Lorenzo Di Cesare</au><au>Ghelardini, Carla</au><au>Kolar, Grant</au><au>Wahlman, Carrie</au><au>Opejin, Adeleye</au><au>Xiao, Cuiying</au><au>Reitman, Marc L</au><au>Tosh, Dilip K</au><au>Hawiger, Daniel</au><au>Jacobson, Kenneth A</au><au>Salvemini, Daniela</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Adenosine [A.sub.3] agonists reverse neuropathic pain via T cell-mediated production of IL-10</atitle><jtitle>The Journal of clinical investigation</jtitle><date>2021-04-01</date><risdate>2021</risdate><volume>131</volume><issue>7</issue><issn>0021-9738</issn><eissn>1558-8238</eissn><abstract>The [A.sub.3] adenosine receptor ([A.sub.3]AR) has emerged as a therapeutic target with [A.sub.3]AR agonists to tackle the global challenge of neuropathic pain, and investigation into its mode of action is essential for ongoing clinical development. Immune cell [A.sub.3]ARs, and their activation during pathology, modulate cytokine release. Thus, the use of immune cells as a cellular substrate for the pharmacological action of [A.sub.3]AR agonists is enticing, but unknown. The present study discovered that Rag- KO mice lacking T and B cells, as compared with WT mice, are insensitive to the anti-allodynic effects of [A.sub.3]AR agonists. Similar findings were observed in interleukin-10 and interleukin-10 receptor knockout mice. Adoptive transfer of [CD4.sup.+] T cells from WT mice infiltrated the dorsal root ganglion (DRG) and restored [A.sub.3]AR agonist-mediated anti-allodynia in Rag-KO mice. [CD4.sup.+] T cells from Adora3-KO or Il10-KO mice did not. Transfer of [CD4.sup.+] T cells from WT mice, but not Il10-KO mice, into Il10- KO mice or Adora3-KO mice fully reinstated the anti-allodynic effects of [A.sub.3]AR activation. Notably, [A.sub.3]AR agonism reduced DRG neuron excitability when cocultured with [CD4.sup.+] T cells in an IL-10-dependent manner. [A.sub.3]AR action on [CD4.sup.+] T cells infiltrated in the DRG decreased phosphorylation of GluN2B-containing N-methyl-D-aspartate receptors at Tyr1472, a modification associated with regulating neuronal hypersensitivity. Our findings establish that activation of [A.sub.3]AR on [CD4.sup.+] T cells to release IL-10 is required and sufficient evidence for the use of [A.sub.3]AR agonists as therapeutics.</abstract><pub>American Society for Clinical Investigation</pub><doi>10.1172/JCI139299</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0021-9738
ispartof The Journal of clinical investigation, 2021-04, Vol.131 (7)
issn 0021-9738
1558-8238
language eng
recordid cdi_gale_infotracmisc_A657723633
source PubMed Central; EZB Electronic Journals Library
subjects Care and treatment
Cell receptors
Development and progression
Genetic aspects
Health aspects
Immune response
Interleukins
Peripheral nerve diseases
title Adenosine [A.sub.3] agonists reverse neuropathic pain via T cell-mediated production of IL-10
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T19%3A55%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Adenosine%20%5BA.sub.3%5D%20agonists%20reverse%20neuropathic%20pain%20via%20T%20cell-mediated%20production%20of%20IL-10&rft.jtitle=The%20Journal%20of%20clinical%20investigation&rft.au=Durante,%20Mariaconcetta&rft.date=2021-04-01&rft.volume=131&rft.issue=7&rft.issn=0021-9738&rft.eissn=1558-8238&rft_id=info:doi/10.1172/JCI139299&rft_dat=%3Cgale%3EA657723633%3C/gale%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-g289t-426c997f7f022cec05c72c0a0afe4be0d7a8b49c1905ebcae17fc26532b1ccfc3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rft_galeid=A657723633&rfr_iscdi=true